All In Biotech

Drug Trial Radar · NCT06672068

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

To Evaluate the Efficacy and Safety of TY-9591 Tablets Combined With Chemotherapy as First-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation

Last checked: Nov 19, 2026Latest source record: Dec 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Feb 20, 2025

Primary completion

Dec 1, 2027

Study completion Dec 1, 2028

Sponsor

Lead sponsor
TYK Medicines, IncIndustry
Sponsor type
Industry
First posted
Nov 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a parallel, randomized, multicenter phase II clinical trial to evaluate the efficacy and safety of TY-9591 combined with platinum-based chemotherapy as first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR sensitive mutations.

Conditions

  • NSCLC

Interventions

  • TY-9591 80mg QD+pemetrexed+Cisplatin/CarboplatinDrug

    TY-9591 80mg QD+pemetrexed 500mg/m²(D1,Q3w)+Carboplatin AUC5/ Cisplatin 75mg/m²(D1,Q3w\*4 cycles)

  • TY-9591 160mg QD+pemetrexed+Cisplatin/CarboplatinDrug

    TY-9591 160mg QD+pemetrexed 500mg/m²(D1,Q3w)+Carboplatin AUC5/ Cisplatin 75mg/m²(D1,Q3w\*4 cycles)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORRTime frame: Up to 33 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.